secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001493152-24-024046
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.03, 5.02, 5.03, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MyMD appoints Glass as President/CMO, Friscia to board; Chapman departs; preferred shares increased
--------------------------------------------------------------------------------

- Mitchell Glass, M.D. appointed President & CMO effective June 13, 2024; no additional compensation.
- Stephen Friscia appointed to board of directors, nominated by PharmaCyte Biotech per SPA.
- Christopher Chapman, M.D. resigned as President, CMO and director effective June 14, 2024; separation includes $125K installments, $25K one-time, COBRA, option acceleration.
- Amendment filed to increase authorized Series G Preferred shares from 8,950 to 12,826,273 for in-kind dividends.
- Chapman's departure amicable; he will focus on Telomir Pharmaceuticals (TELO).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315224024046/0001493152-24-024046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315224024046/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-024046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer